Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vipin Arora

Showing results (61-70 of 75) with videos related to

Pageof 8
Sort By:
Gene|March 30, 2021
Gut-microbiota modulation: The impact of thegut-microbiotaon osteoarthritisVipin Arora, Gurjit Singh, InSug O-Sullivan, et al.
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
BMJ Open Gastroenterology|March 31, 2023
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitisMarla C Dubinsky, Vipul Jairath, Brian G Feagan, et al.
Intestinal Research|May 9, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studiesTaku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.
Molecular Pain|April 8, 2021
Systemic administration of a β2-adrenergic receptor agonist reduces mechanical allodynia and suppresses the immune response to surgery in a rat model of persistent post-incisional hypersensitivityVipin Arora, Carlos Eduardo Morado-Urbina, Young S Gwak, et al.
Crohn'S & Colitis 360|February 13, 2023
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
The New England Journal of Medicine|June 28, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisGeert D'Haens, Marla Dubinsky, Taku Kobayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Pageof 8

Showing results (61-70 of 75) with videos related to

Sort By:
Pageof 8
Gene|March 30, 2021
Gut-microbiota modulation: The impact of thegut-microbiotaon osteoarthritisVipin Arora, Gurjit Singh, InSug O-Sullivan, et al.
Journal of Gastroenterology|December 24, 2013
Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitisYasuo Suzuki, Satoshi Motoya, Hiroyuki Hanai, et al.
BMJ Open Gastroenterology|March 31, 2023
Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitisMarla C Dubinsky, Vipul Jairath, Brian G Feagan, et al.
Intestinal Research|May 9, 2024
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studiesTaku Kobayashi, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.
Molecular Pain|April 8, 2021
Systemic administration of a β2-adrenergic receptor agonist reduces mechanical allodynia and suppresses the immune response to surgery in a rat model of persistent post-incisional hypersensitivityVipin Arora, Carlos Eduardo Morado-Urbina, Young S Gwak, et al.
Crohn'S & Colitis 360|February 13, 2023
Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.
Inflammatory Bowel Diseases|January 25, 2024
Extended Induction and Prognostic Indicators of Response in Patients Treated with Mirikizumab with Moderately to Severely Active Ulcerative Colitis in the LUCENT TrialsGeert D'Haens, Peter D R Higgins, Laurent Peyrin-Biroulet, et al.
The New England Journal of Medicine|June 28, 2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative ColitisGeert D'Haens, Marla Dubinsky, Taku Kobayashi, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020
Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.
Annals of the Rheumatic Diseases|August 12, 2017
Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM studyEdward C Keystone, Peter C Taylor, Yoshiya Tanaka, et al.
Pageof 8